Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (13666)	5/25/2000 12:17:00 PM
From: Bluegreen	Respond to of 17367

Cacaito, thanks for the response. Hopefully Peptobismol won't ever have to go through the FDA approval process!!!!!!! On another note, would you consider listening to recent Castello audio on anti-Cd11a? Protocol seems to be Sub Q injection once a week for twelve weeks. I would be interested in your thoughts on his statement made about P value of this Psoriasis trial AND his comments about what DNA reportedly thought of this trial's P value also so far. I, of course don't want any false hopes and know you are the one ask. BTW, I know there probably will be competition, etc. but I figure DNA might know what they are doing.

To: Cacaito who wrote (13666)	5/26/2000 11:00:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

E.Coli revisited. Cacaito, please don't lurk, but rather help out one more time. XOMA reports the following rBPI21 synergizes with Ceftriaxone to kill kill cefttriaxone resistant organisms. EC 004. EC 600 and EC 664. Another graph is titled rBPI Kills Rough and Smooth Strains of E.Coli and shows rBPI21 and rBPI23 killinf E.coli J5 and E. coli 07:k1 Since I have nothing specific on 0157 I do not know what it does for this strain. Again XOMA is talking about killing not binding to endotoxin. Understand your exotoxin point and if that is the main problem with 0157 then killing may not be enough.